IMMERVISION
16.6.2015 09:01:14 CEST | Business Wire | Pressemeddelelse
You may not smell the exhaust of the race cars or feel the stadium rumble as points flash onto the scoreboard, but the unprecedented ability to experience a live broadcast event in 360-degree from any angle promises to change the viewer experience forever. Thanks to ImmerVision’s expertise in 360-degree optic technology and C360 Technologies extensive experience in 360-degree live broadcast camera systems and event capturing; this single panomorph lens system is quickly heading to broadcasters, event promoters, and content-providers worldwide, promising to outdate current systems overnight.
The breakthrough is made possible using ImmerVision’s panomorph super-wide-angle lens technology. The 6K-quality lens captures 360-degree views without panning, stitching or blind spots. This lens certified ImmerVision Enables, The 360-degree Video Standard, already well known in the security industry, enables users to view events from any angle, watch multiple views at once on the same screen, and share an immersive experience across multiple platforms and devices.
Broadcasters, for the first time, can CREATE immersive moments where an unlimited number of viewers on any platform — from desktops to mobile devices — can SHARE & EXPERIENCE live 360-degree events from any angle, at any time.
“The quality and performance ImmerVision has achieved is simply phenomenal and well-beyond what we expected when we approached them to create a custom lens solution to our specification,” says Evan Wimer, co-founder and chairman of C360 Technologies, Inc. “In auto racing viewers will feel like they are in the pits with whizzing impact wrenches and squealing tires. In golf, they’ll experience history-making putts more up-close and personal. At any live event our system puts viewers in control of their experience and provides broadcasters unlimited new angles.”
ImmerVision’s executive vice-president and chief commercial officer, Alessandro Gasparini, explains, “The combination of 6K panomorph lens and C360 camera technology puts consumers in the midst of the ultimate fan experience. This will revolutionize the way people watch live broadcasts, Pay-Per-View events, and experience virtual reality with head mounted displays.”
About ImmerVision
Leading innovation in 360-degree panoramic
imaging, ImmerVision licenses its patented panomorph optical and
software technology to global lens producers, product manufacturers and
software developers. Panomorph lenses are the only ones that can be
adapted to any camera, any sensor, and any consumer, commercial and
government market. ImmerVision Enables is the recognized standard for
360-degree solutions and applications. www.immervisionenables.com
About C360 Technologies
A pioneer in "live" 360° video
technology providing real-time video control to viewers by using
360-degree Live Broadcast Camera Systems. C360 engineers professional
360-degree camera systems that enable broadcasters, promoters and
organizations to capture, record and stream live sports, music and
events. With over 10 years experience in the broadcast industry, C360
has captured events for NASCAR, PGA, Turner Broadcasting/Turner Sports &
Entertainment Digital Networks to name a few. www.c360live.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150616005497/en/
Contact:
ImmerVision
Louis Brun, +1-514-315-5863
louis.brun@immervision.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum